C-reactive protein, bezafibrate, and recurrent coronary events in patients with chronic coronary heart disease

American Heart Journal

Volumn 154, Issue 6, 2007, Pages 1095-1101

  Haim, Moti ^a   Benderly, Michal ^b   Tanne, David ^b   Matas, Zipora ^c   Boyko, Valentina ^b   Fisman, Enrique Z ^b   Tenenbaum, Alexander ^b   Zimmlichman, Reuven ^c   Battler, Alexander ^a   Goldbourt, Uri ^b   Behar, Solomon ^b  

^a RABIN MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c WOLFSON MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; C REACTIVE PROTEIN; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT DISEASE; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION;

ANTILIPEMIC AGENTS; BEZAFIBRATE; C-REACTIVE PROTEIN; CORONARY DISEASE; DEATH, SUDDEN, CARDIAC; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; RECURRENCE; RISK FACTORS;

EID: 36148989607     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.07.026     Document Type: Article

References (38)

1. Ridker P.M., Glynn R.J., and Hennekens C.H. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97 (1998) 2007-2011
2. Ridker P.M., Buring J.E., Shih J., et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98 (1998) 731-733
3. Ridker P.M., Cushman M., Stampfer M.J., et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 97 (1998) 425-428
4. Curb J.D., Abbott R.D., Rodriguez B.L., et al. C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation 107 (2003) 2016-2020
5. Biasucci L.M., Liuzzo G., Grillo R.L., et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 99 (1999) 855-860
6. Bickel C., Rupprecht H.J., Blankenberg S., et al. Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 89 (2002) 901-908
7. de Winter R.J., Bholasingh R., Lijmer J.G., et al. Independent prognostic value of C-reactive protein and troponin I in patients with unstable angina or non-Q-wave myocardial infarction. Cardiovasc Res 42 (1999) 240-245
8. Ferreiros E.R., Boissonnet C.P., Pizarro R., et al. Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation 100 (1999) 1958-1963
9. Lenderink T., Boersma E., Heeschen C., et al. Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA. Eur Heart J 24 (2003) 77-85
10. Morrow D.A., Rifai N., Antman E.M., et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 31 (1998) 1460-1465
11. Pearson T.A., Mensah G.A., Hong Y., et al. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: application to Clinical and Public Health Practice: overview. Circulation 110 (2004) e543-e544
12. Zebrack J.S., Anderson J.L., Maycock C.A., et al. Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol 89 (2002) 145-149
13. Haverkate F., Thompson S.G., Pyke S.D., et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349 (1997) 462-466
14. Arroyo-Espliguero R., Avanzas P., Cosin-Sales J., et al. C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J 25 (2004) 401-408
15. Ridker P.M., Cannon C.P., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
16. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352 (2005) 29-38
17. Gomez-Gerique J.A., Ros E., Olivan J., et al. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis 162 (2002) 245-251
18. Cortellaro M., Cofrancesco E., Boschetti C., et al. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment. Thromb Haemost 83 (2000) 549-553
19. Jonkers I.J., Mohrschladt M.F., and Westendorp R.G. Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. Am J Med 112 (2002) 275-280
20. The Bezafibrate Infarction Prevention (BIP) Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102 (2000) 21-27
21. Ridker P.M., Hennekens C.H., Buring J.E., et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
22. Ridker P.M., Rifai N., Pfeffer M.A., et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 98 (1998) 839-844
23. Retterstol L., Eikvar L., Bohn M., et al. C-reactive protein predicts death in patients with previous premature myocardial infarction-a 10 year follow-up study. Atherosclerosis 160 (2002) 433-440
24. Mueller C., Buettner H.J., Hodgson J.M., et al. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation 105 (2002) 1412-1415
25. Sabatine M.S., Morrow D.A., de Lemos J.A., et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 105 (2002) 1760-1763
26. Horne B.D., Muhlestein J.B., Carlquist J.F., et al. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. J Am Coll Cardiol 36 (2000) 1774-1780
27. Bogaty P., Poirier P., Simard S., et al. Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina. Circulation 103 (2001) 3062-3068
28. Leu H.B., Lin C.P., Lin W.T., et al. Risk stratification and prognostic implication of plasma biomarkers in nondiabetic patients with stable coronary artery disease: the role of high-sensitivity C-reactive protein. Chest 126 (2004) 1032-1039
29. Garcia-Moll X., Zouridakis E., Cole D., et al. C-reactive protein in patients with chronic stable angina: differences in baseline serum concentration between women and men. Eur Heart J 21 (2000) 1598-1606
30. Zebrack J.S., Muhlestein J.B., Horne B.D., et al. C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. J Am Coll Cardiol 39 (2002) 632-637
31. Bogaty P., Brophy J.M., Boyer L., et al. Fluctuating inflammatory markers in patients with stable ischemic heart disease. Arch Intern Med 165 (2005) 221-226
32. Ockene I.S., Matthews C.E., Rifai N., et al. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 47 (2001) 444-450
33. Rizos E., Kostoula A., Elisaf M., et al. Effect of ciprofibrate on C-reactive protein and fibrinogen levels. Angiologia 53 (2002) 273-277
34. Sebestjen M., Keber I., Zegura B., et al. Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors. Thromb Haemost 92 (2004) 1129-1135
35. Ikewaki K., Tohyama J., Nakata Y., et al. Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men-a nuclear magnetic resonance study. J Atheroscler Thromb 11 (2004) 278-285
36. Wang T.D., Chen W.J., Lin J.W., et al. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis 170 (2003) 315-323
37. Despres J.P., Lemieux I., Pascot A., et al. Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome. Arterioscler Thromb Vasc Biol 23 (2003) 702-703
38. Kleemann R., Gervois P.P., Verschuren L., et al. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood 101 (2003) 545-551